Upadacitinib: Mechanism of action, clinical, and translational science

by Mohamed‐Eslam F. Mohamed, Sumit Bhatnagar, Julie M. Parmentier, Priscila Nakasato, Peter Wung
Published 2024-01-01

Population pharmacokinetics and exposure‐response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis

by Sumit Bhatnagar, Doerthe Eckert, Sven Stodtmann, In‐Ho Song, Peter Wung, Wei Liu, Mohamed‐Eslam F. Mohamed
Published 2024-02-01

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials

by Gerd R. Burmester, Jayne Stigler, Andrea Rubbert-Roth, Yoshiya Tanaka, Valderilio F. Azevedo, Derek Coombs, Ivan Lagunes, Ralph Lippe, Peter Wung, Lianne S. Gensler
Published 2024-04-01

Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2

by Uta Kiltz, Mitsumasa Kishimoto, Jessica A. Walsh, Percival Sampaio-Barros, Manish Mittal, Christopher D. Saffore, Peter Wung, Fabiana Ganz, Ana Biljan, Denis Poddubnyy
Published 2023-05-01

Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study

by Iain B. McInnes, Koji Kato, Marina Magrey, Joseph F. Merola, Mitsumasa Kishimoto, Derek Haaland, Liang Chen, Yuanyuan Duan, Jianzhong Liu, Ralph Lippe, Peter Wung
Published 2022-10-01

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study

by Xenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, Robert D. Inman, Hideto Kameda, Yihan Li, Xianwei Bu, Anna Shmagel, Peter Wung, In-Ho Song, Atul Deodhar
Published 2023-09-01